Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

You don’t go more than 40 years in biotech with­out ever get­ting a prod­uct to mar­ket un­less you can learn the art of writ­ing a pro­mo­tion­al press re­lease. And In­ovio cap­tures the prize in bait­ing the hook.

Tues­day morn­ing In­ovio, which has been strug­gling to get its Covid-19 vac­cine lined up for mass man­u­fac­tur­ing, put out a re­lease that touched on vir­tu­al­ly every hot but­ton in pan­dem­ic PR.

There was, first and fore­most, an in­ter­im snap­shot of ef­fi­ca­cy from their Phase I pro­gram for INO-4800.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.